PROCEPT BioRobotics, a company specializing in surgical robotics for urology, announced it will release its financial results for the first quarter of 2026 on April 29, 2026, after market close. The company will host a conference call for investors to discuss the results at 4:30 p.m. Eastern Time. PROCEPT BioRobotics is known for its AQUABEAM and HYDROS robotic systems, which provide innovative treatments for benign prostatic hyperplasia (BPH), a common prostate condition affecting millions of men. The upcoming report will provide insights into the company's financial performance and ongoing advancements in robotic urology solutions.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
